Latest News
MHA advises Ariceum Therapeutics with Theragnostics acquisition
The acquisition of Theragnostics Ltd delivers an expanded portfolio of therapeutic and diagnostic assets in late preclinical and early clinical development for Ariceum
MHA has successfully advised Ariceum Therapeutics, a Berlin-based private biotech company, on the acquisition of Theragnostics Ltd., a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours.
You'll need to
subscribe to unlock this content. Already subscribed? Login?
